Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220097 | 0.83 | SIGMAR1 (0.62) | SMN1; SMN2KMT2AGAAMEN1ALDH1A1 | |
| SCHEMBL1160126 | 0.83 | SIGMAR1 (0.62) | SMN1; SMN2KDM5CKDM4CKMT2AGAA | |
| SCHEMBL4751222 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2JAK2JAK1KMT2AMEN1 | |
| SCHEMBL13995932 | 0.81 | SIGMAR1 (0.61) | SMN1; SMN2KDM5CKDM4CKMT2AGAA | |
| Hydrochloric Acid SCHEMBL28273325 | 0.81 | SIGMAR1 (0.61) | SMN1; SMN2KDM5CKDM4CKMT2AGAA | |
| Hydrochloric Acid SCHEMBL10901935 | 0.81 | SIGMAR1 (0.61) | SMN1; SMN2KDM5CKDM4CKMT2AGAA | |
| SCHEMBL6707987 | 0.81 | GRM2 (0.47) | SMN1; SMN2JAK2JAK1TNIKMCHR1 | |
| SCHEMBL4748942 | 0.80 | ALDH1A1 (0.61) | SMN1; SMN2MCHR1GRM2KMT2AMEN1 | |
| SCHEMBL1427302 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2JAK2JAK1TNIKKMT2A | |
| SCHEMBL17468364 | 0.80 | CXCR4 (0.55) | SMN1; SMN2KMT2AGAAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | BOERNSEN KLAUS OLAF (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | BOERNSEN KLAUS OLAF | 2010-09-02 | — | — | US | disclosed |
| EP-2194049-A1 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | BORNSEN KLAUS OLAF | 2009-09-24 | — | — | US | disclosed |
| US-7557105-B2 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2009-07-07 | — | — | US | disclosed |
| CN-101468984-A | N-oxyde of n-phenyl-2-pyrimidine-amine derivatives | NOVARTIS PHARMA GMBH (CH) | 2009-07-01 | — | — | CN | disclosed |
| CN-100467461-C | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1783126-A2 | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | disclosed |
| CN-1646519-A | N-oxides of N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2005-07-27 | — | — | CN | disclosed |
| EP-1470120-A1 | N-OXYDE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003062220-A1 | N-OXYDE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222362-A1 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES | NUDT1, NT5C2, NOX5 | SMN1; SMN2 500/4885PTGS1 305/4885PTGS2 140/4885 |
| US-20110294820-A1 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives | NUDT1, PNP, NME2 | SMN1; SMN2 711/4885PTGS1 434/4885PTGS2 277/4885 |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | MKI67, CDK4, NME2 | SMN1; SMN2 769/4885PTGS1 414/4885PTGS2 452/4885 |
| US-20140323494-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | SMN1; SMN2 597/4885PTGS1 463/4885PTGS2 285/4885 |
| US-20090239879-A1 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, NME2 | SMN1; SMN2 711/4885PTGS1 434/4885PTGS2 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.